SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the closing of an ...

AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE: TAK). The Japanese drug maker will use Iambic's AI ...

Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery ...

Iambic Therapeutics has advanced its first pipeline candidate into the clinic, an AI-designed treatment for human epidermal growth factor receptor 2 (HER2)-driven cancers that moved from discovery to ...

SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, published on major advances ...

Busy Iambic Therapeutics has picked up more than $100 million in new funding as it looks to advance its portfolio of AI-discovered therapeutics. The oversubscribed funding round comes on the heels of ...

Iambic, a clinical-stage life science and technology company that uses artificial intelligence to develop medicines has raised more than $100 million in an oversubscribed financing round. The Nov. 10 ...

Drug discovery isn’t only about finding new targets. There’s still plenty of opportunity to find better ways to hit targets that are already drugged, according to Tom Miller, CEO of startup Iambic ...

LONDON (Reuters) - Biotech firm Iambic Therapeutics unveiled on Tuesday what it says is a breakthrough artificial intelligence model that could drastically reduce the time and money needed to develop ...

Multi-year partnership will utilize Iambic’s broad suite of AI drug discovery technologies and wet lab capabilities to advance collaboration programs initially in Takeda’s Oncology and ...